Healthcare providers continue to worry about the impact of 23andMe's health risk reports but there is also growing acceptance of the DTC testing model.
The new channel, to be launched in the second quarter, is part of the company's plan to make genetic testing affordable and accessible to everyone.
Direct-to-consumer genetic testing firm 23andMe has a newly cleared colorectal cancer risk test.
LunaDNA parent company LunaPBS will combine its technology platform with Genetic Alliance's PEER system to advance patient-centric research.
In an effort to lift patient access barriers, the company is launching a model whereby consumers will be able to initiate test orders online.
Blockchain-based startup EncrypGen will take advantage of Murrieta Genomics' sequencing lab and business services to market its Gene-Chain platform for data sharing.
As consumer genomics firms ramp up marketing for Alzheimer's risk tests, one support group says experts should help people understand the results and potential negative effects.
Myriad CEO Mark Capone said earnings during the quarter exceeded expectations based on strong volume growth from hereditary cancer and new products.
The genetic testing community is having a tough time deciphering FDA's intentions based on its authorization of 23andMe’s PGx test and a recent safety alert.
Time reports that some experts have raised concerns about 23andMe's new direct-to-consumer pharmacogenetic tests.
Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.
Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.
The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.
In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.